Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tumor tissue and blood samples from patients with small cell lung cancer registered on CALGB-140202.
Genetic: DNA analysis
Genetic: gene expression analysis
Genetic: gene mapping
Genetic: mutation analysis
Other: laboratory biomarker analysis
|Official Title:||Genomics of Small Cell Lung Carcinoma|
- Identification of genetic alterations in human SCLC (driver or passenger mutations) [ Designated as safety issue: No ]
- Differences in gene expression between samples with or without mutations [ Designated as safety issue: No ]
|Study Start Date:||February 2012|
|Estimated Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
- To identify the major genetic alterations in human small cell lung cancer (SCLC) using next-generation sequencing and focusing on mutations in coding sequence.
- To follow up with in-depth assessment of candidate oncogenes and tumor suppressor genes using gene expression analysis, cell culture systems, and murine models of SCLC.
OUTLINE: DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01503619
|Principal Investigator:||David MacPherson, PhD||Carnegie Institution for Science|